CAPTRUST Financial Advisors’s Compass Therapeutics CMPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.2K Sell
10,721
-21,888
-67% -$45.1K ﹤0.01% 3348
2026
Q2
$71.4K Buy
32,609
+10,933
+50% +$32.3K ﹤0.01% 3093
2026
Q1
$115K Buy
21,676
+830
+4% +$4.79K ﹤0.01% 2792
2025
Q4
$112K Buy
20,846
+322
+2% +$1.49K ﹤0.01% 2598
2025
Q3
$71.8K Buy
20,524
+199
+1% +$629 ﹤0.01% 2537
2025
Q2
$52.8K Buy
20,325
+332
+2% +$685 ﹤0.01% 2421
2025
Q1
$38K Buy
+19,993
New +$53.2K ﹤0.01% 2299

Other funds holding CMPX

CAPTRUST Financial Advisors's CMPX Position: Q3 2026 in Review

CAPTRUST Financial Advisors reduced its Compass Therapeutics (CMPX) stake by 67% in Q3 2026, selling an estimated $45.1K and leaving 10,721 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

CAPTRUST Financial Advisors first reported a position in CMPX in Q1 2025 and has held it in 7 quarters since. The position peaked at $115K in Q1 2026. 171 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • CAPTRUST Financial Advisors held 10,721 shares of Compass Therapeutics worth $11.2K as of Q3 2026.
  • CAPTRUST Financial Advisors sold 21,888 Compass Therapeutics shares in Q3 2026, an estimated $45.1K.
  • Compass Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3348 holding.
  • CAPTRUST Financial Advisors first reported a position in Compass Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • CAPTRUST Financial Advisors's Compass Therapeutics position peaked at $115K in Q1 2026.
  • 171 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.